David Rioux
Family Medicine · Machias, MENPI 1316084650
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 594 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 594 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- AstraZeneca$996
- GSK$904
- Novo Nordisk$900
- AbbVie$884
- Lundbeck LLC$737
- plus $5K from 25 others
What the payments were for
- Food & beverage$10,07797%
- Education$3403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 80 | $1,153 |
| AstraZeneca | 59 | $996 |
| GSK | 62 | $904 |
| Novo Nordisk | 53 | $900 |
| AbbVie(2 entities) | 45 | $884 |
| Lundbeck LLC | 33 | $737 |
| Sanofi-aventis U.S. LLC | 37 | $693 |
| Merck | 37 | $646 |
| Bayer | 25 | $459 |
| Astellas Pharma US Inc | 12 | $427 |
| Exact Sciences | 18 | $398 |
| Johnson & Johnson | 33 | $397 |
| Boehringer Ingelheim | 16 | $278 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $257 |
| Abbott | 9 | $187 |
| Otsuka America Pharmaceutical, Inc. | 9 | $176 |
| Lilly USA, LLC | 11 | $163 |
| E.r. Squibb & Sons, L.L.C. | 10 | $155 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $129 |
| Eisai Inc. | 7 | $112 |
| Corcept Therapeutics | 3 | $84 |
| Novartis | 3 | $72 |
| Paratek Pharmaceuticals, Inc. | 2 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $30 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
How this compares
$10,417 in reported general payments places this provider in the 95th percentile of 466 family medicine providers in Maine.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 173 | $207,146 |
| OzempicSemaglutide | 166 | $183,945 |
| FarxigaDapagliflozin Propanediol | 86 | $102,713 |
| JardianceEmpagliflozin | 71 | $98,783 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $75,297 |
| XareltoRivaroxaban | 45 | $63,113 |
| JanuviaSitagliptin Phosphate | 29 | $42,177 |
| KerendiaFinerenone | 20 | $33,316 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $27,521 |
| TrulicityDulaglutide | 24 | $24,450 |
| MovantikNaloxegol Oxalate | 21 | $23,081 |
| MyrbetriqMirabegron | 19 | $19,994 |
| TrintellixVortioxetine Hydrobromide | 13 | $18,571 |
| DapagliflozinDapagliflozin Propanediol | 27 | $15,656 |
| EntrestoSacubitril/Valsartan | 16 | $14,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,153 | $207,146173 claims |
| Novo NordiskOzempic | $900 | $183,945166 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $996 | $135,923152 claims |
| Boehringer IngelheimJardiance | $278 | $98,78371 claims |
| GSKTrelegy Ellipta | $904 | $75,29776 claims |
| Johnson & JohnsonXarelto | $397 | $63,11345 claims |
| MerckJanuvia | $646 | $42,17729 claims |
| BayerKerendia | $459 | $33,31620 claims |
| Lilly USA, LLCTrulicity | $163 | $24,45024 claims |
| Astellas Pharma US IncMyrbetriq | $427 | $19,99419 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $257 | $18,57113 claims |
| NovartisEntresto | $72 | $14,19816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 466 family medicine providers in Maine.
Other family medicine in Machias
- Kristy Murray-PulsiferSouth Portland$55K
- Albert HartmanLewiston$33K
- Brian KnightonFreeport$29K
- Edward YoonPortland$27K
- Jennifer FreeseVeazie$19K
- Kohar der SimonianFalmouth$18K
- Jessica Bloom FosterBangor$14K
- Cecily CannonKennebunk$14K
- Maria AtkinsPortland$14K
- Julia McDonaldAugusta$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.